Industry Insights & Trends
Fast-Track Your Therapy Pipeline with CGT Global’s Clinical Capabilities
By: Joanna Wirkus Despite exponential progress in the field of biology, inherited and preventable diseases continue to burden billions of people worldwide. Bridging the gap between laboratory discoveries and transformative clinical therapies remains a significant challenge, , and an urgent opportunity. High-quality biospecimens are foundational to this effort, enabling the advancement of cell and gene…
For More InformationWhen Politics Blocks Progress: Funding Health Discoveries in Peril
Shifting Political Priorities Threaten the Bedrock of Health Science Investment By: Joanna Wirkus PhD July 2025 ** For scientists under pressure from shifting funding priorities, CGT Global has curated a FREE downloadable funding toolkit with resources to support your long-term funding acquisition strategy. Complete with a grant planning checklist, a curated list of 35+ funding…
For More InformationCGT Sourcing Guide 2025: How to Build a Resilient Supply Chain Amid Tariff Pressures
By CGT Global The latest round of U.S. tariffs didn’t just shake up the headlines—it shook the very foundations of global pharma supply chains. And while most of the buzz has focused on traditional drugmakers, let’s be clear: cell and gene therapy manufacturers aren’t sitting this one out. For companies working with high-value, time-sensitive materials…
For More InformationHow Natural Killer Cells are Revolutionizing Cancer Treatment
By Joanna Wirkus What makes Natural Killer (NK) Cells the Perfect Weapon Against Cancer? Unlike the T cells of the adaptive immune system, innate natural killer (NK) cells protect the body against tumors without prior programming. They recognize and become activated by abnormal cells that lack or express key outer membrane markers characteristic of cancer.…
For More Information